execut
summari
sign
normal
mental
statu
step
patient
assign
risk
class
stratifi
class
iiv
basi
point
assign
demograph
variabl
age
sex
nurs
home
resid
comorbid
condit
summar
physic
examin
find
laboratori
andor
radiograph
find
patient
risk
class
ii
usual
requir
hospit
risk
class
iii
may
requir
brief
hospit
risk
class
iv
v
usual
requir
hospit
note
social
factor
outpati
support
mechan
probabl
adher
includ
assess
laboratori
test
patient
thought
pneumonia
undergo
chest
radiographi
follow
laboratori
valu
determin
patient
hospit
complet
blood
cell
count
differenti
serum
creatinin
blood
urea
nitrogen
glucos
electrolyt
liver
function
test
hiv
serolog
inform
consent
consid
especi
person
age
year
oxygen
satur
assess
pretreat
blood
cultur
well
gram
stain
cultur
expector
sputum
select
patient
microbiolog
studi
tuberculosi
legionella
infect
prefer
test
detect
legionella
speci
urinari
antigen
assay
legionella
pneumophila
serogroup
cultur
select
media
rational
perform
microbiolog
studi
establish
etiolog
diagnosi
base
attempt
improv
care
individu
patient
pathogenspecif
treatment
improv
care
patient
advanc
knowledg
detect
epidemiolog
import
organ
legionella
penicillinresist
streptococcu
pneumonia
methicillinresist
staphylococcu
aureu
implement
contacttrac
antimicrobi
prophylaxi
appropri
set
case
neisseria
meningitidi
infect
haemophilu
influenza
type
b
infect
tuberculosi
prevent
antibiot
abus
reduc
antibiot
expens
antimicrobi
therapi
recommend
provid
pathogenspecif
treatment
case
etiolog
diagnosi
establish
strongli
suspect
inform
avail
initi
subsequ
report
chang
antimicrobi
agent
costeffect
least
toxic
narrow
spectrum
encourag
recommend
treat
patient
requir
empir
antibiot
select
base
sever
ill
pathogen
probabl
resist
pattern
pneumonia
commonli
implic
etiolog
agent
comorbid
condit
recommend
outpati
administr
macrolid
doxycyclin
fluoroquinolon
enhanc
activ
pneumonia
patient
hospit
recommend
administr
fluoroquinolon
alon
extendedspectrum
cephalosporin
cefotaxim
ceftriaxon
plu
macrolid
patient
hospit
intens
care
unit
icu
receiv
ceftriaxon
cefotaxim
ampicillinsulbactam
piperacillintazobactam
combin
fluoroquinolon
macrolid
blactam
note
recommend
intraven
antibiot
may
switch
oral
agent
patient
improv
clinic
hemodynam
stabl
abl
ingest
drug
patient
show
clinic
respons
within
day
chang
evid
chest
radiograph
usual
lag
behind
clinic
respons
repeat
chest
radiographi
gener
indic
patient
respond
failur
respond
usual
indic
incorrect
diagnosi
host
failur
inappropri
antibiot
inappropri
dose
rout
administr
unusu
unanticip
pathogen
advers
drug
reaction
complic
pulmonari
superinfect
empyema
prognosi
frequent
caus
lethal
communityacquir
pneumonia
pneumonia
legionella
frequent
reason
failur
respond
progress
pathophysiolog
chang
despit
appropri
antibiot
treatment
pneumococc
pneumonia
pneumonia
common
identifi
etiolog
agent
pneumonia
virtual
studi
account
twothird
bacterem
pneumonia
case
pneumococci
frequent
caus
lethal
communityacquir
pneumonia
manag
complic
recent
year
evolut
multidrug
resist
blactam
amoxicillin
cefotaxim
ceftriaxon
gener
regard
drug
choic
although
pneumonia
caus
resist
strain
mic
mgml
may
respond
readili
pneumonia
caus
suscept
strain
activ
macrolid
doxycyclin
blactam
includ
cefuroxim
good
penicillinsuscept
strain
less
predict
strain
show
reduc
penicillinsuscept
vancomycin
linezolid
quinupristin
dalfopristin
drug
predict
vitro
activ
fluoroquinolon
gener
activ
strain
suscept
resist
penicillin
recent
report
indic
increas
resist
select
locat
correl
excess
fluoroquinolon
use
prevent
major
prevent
measur
use
influenza
vaccin
use
pneumococc
vaccin
accord
guidelin
advisori
council
immun
practic
center
diseas
control
prevent
cdc
perform
indic
recommend
perform
indic
includ
collect
blood
cultur
specimen
antibiot
treatment
institut
antibiot
treatment
within
h
hospit
sinc
support
basi
evidencebas
trial
addit
perform
indic
recommend
laboratori
test
legionella
patient
hospit
icu
demonstr
infiltr
chest
radiograph
patient
intern
classif
diseas
edit
code
pneumonia
measur
blood
gase
puls
oximetri
within
h
admiss
lower
respiratori
tract
infect
major
caus
death
world
major
caus
death
due
infecti
diseas
unit
state
recent
advanc
field
includ
identif
new
pathogen
chlamydia
pneumonia
hantaviru
new
method
microbi
detect
pcr
new
antimicrobi
agent
macrolid
blactam
agent
fluoroquinolon
oxazolidinon
streptogramin
despit
extens
studi
condit
medicin
controversi
term
manag
guidelin
manag
publish
american
thorac
societi
british
thorac
societi
canadian
infecti
diseas
societi
well
infecti
diseas
societi
america
idsa
present
guidelin
repres
revis
recommend
idsa
compar
previou
guidelin
guidelin
intend
reflect
updat
inform
provid
extens
recommend
select
area
indic
evolut
opinion
therapeut
guidelin
restrict
communityacquir
pneumonia
cap
immunocompet
adult
recommend
given
alphabet
rank
reflect
strength
roman
numer
rank
reflect
qualiti
support
evid
tabl
customari
qualiti
standard
idsa
acknowledg
set
standard
construct
deal
multitud
variabl
influenc
decis
regard
site
care
diagnost
evalu
select
antibiot
thu
standard
supplant
good
clinic
judgement
magnitud
cap
commonli
defin
acut
infect
pulmonari
parenchyma
associ
least
symptom
acut
infect
accompani
presenc
acut
infiltr
chest
radiograph
auscultatori
find
consist
pneumonia
alter
breath
sound
moder
evid
support
recommend
use
c
poor
evid
support
recommend
moder
evid
support
recommend
use
e
good
evid
support
recommend
use
qualiti
evid
evid
least
random
control
trial
ii
evid
least
welldesign
clinic
trial
without
random
iii
evid
opinion
respect
author
base
clinic
experi
descript
studi
report
expert
committe
local
rale
patient
hospit
resid
longtermcar
facil
day
onset
symptom
symptom
acut
lower
respiratori
infect
may
includ
sever
studi
least
follow
fever
hypothermia
rigor
sweat
new
cough
without
sputum
product
chang
color
respiratori
secret
patient
chronic
cough
chest
discomfort
onset
dyspnea
patient
also
nonspecif
symptom
fatigu
myalgia
abdomin
pain
anorexia
headach
pneumonia
sixth
common
caus
death
unit
state
overal
rate
death
due
pneumonia
influenza
increas
basi
code
death
certif
unit
state
much
increas
due
greater
proport
person
age
year
howev
ageadjust
rate
also
increas
suggest
factor
may
contribut
chang
epidemiolog
pneumonia
includ
greater
proport
popul
underli
medic
condit
increas
risk
respiratori
infect
annual
million
case
cap
result
million
physician
visit
hospit
death
unit
state
incid
cap
requir
hospit
estim
person
per
popul
per
person
age
year
although
mortal
rang
among
hospit
patient
varieti
studi
averag
mortal
estim
patient
hospit
incid
cap
heavili
weight
toward
winter
month
knowledg
prognosi
diseas
allow
physician
inform
patient
expect
natur
histori
ill
likelihood
potenti
complic
probabl
success
treatment
understand
prognosi
cap
particular
clinic
relev
sinc
rang
rapid
recoveri
symptom
without
function
impair
seriou
morbid
complic
death
abil
accur
predict
medic
outcom
case
cap
major
impact
manag
decis
hospit
patient
treat
outpati
figur
perhap
singl
import
clinic
decis
made
physician
entir
cours
ill
direct
bear
locat
intens
laboratori
evalu
antibiot
therapi
cost
estim
total
treatment
cost
episod
cap
manag
hospit
us
dollar
higher
cost
outpati
treatment
numer
studi
identifi
risk
factor
death
case
cap
factor
welldefin
prepenicillin
era
studi
adult
show
increas
risk
alcohol
consumpt
increas
age
presenc
leukopenia
presenc
bacteremia
radiograph
chang
recent
studi
confirm
find
independ
associ
increas
mortal
also
demonstr
varieti
comorbid
ill
activ
malign
immunosuppress
neurolog
diseas
congest
heart
failur
coronari
arteri
diseas
diabet
mellitu
sign
symptom
independ
associ
increas
mortal
consist
dyspnea
chill
alter
mental
statu
hypothermia
hyperthermia
tachypnea
hypotens
diastol
systol
laboratori
radiograph
find
independ
associ
increas
mortal
hyponatremia
hyperglycemia
azotemia
hypoalbuminemia
hypoxemia
liver
function
test
abnorm
pleural
effus
infect
due
gramneg
bacilli
aureu
postobstruct
pneumonia
aspir
pneumonia
also
independ
associ
higher
mortal
despit
knowledg
regard
associ
clinic
laboratori
radiograph
factor
patient
mortal
wide
geograph
variat
hospit
admiss
rate
cap
variat
suggest
physician
use
uniform
strategi
relat
decis
hospit
prognosi
fact
physician
often
overestim
risk
death
patient
cap
degre
overesti
figur
evalu
diagnosi
manag
communityacquir
pneumonia
includ
site
durat
type
treatment
blactam
cefotaxim
ceftriaxon
blactam
blactamas
inhibitor
fluoroquinolon
levofloxacin
moxifloxacin
gatifloxacin
anoth
fluoroquinolon
enhanc
antipneumococc
activ
macrolid
erythromycin
clarithromycin
azithromycin
cbc
complet
blood
cell
count
icu
intens
care
unit
test
select
patient
see
text
diagnost
evalu
etiolog
see
tabl
special
consider
mation
independ
associ
decis
hospit
past
year
least
studi
use
multivari
analysi
identifi
predictor
prognosi
patient
cap
pneumonia
port
develop
methodolog
sound
clinic
predict
rule
quantifi
shortterm
mortal
patient
ill
use
guidelin
rule
may
help
physician
make
decis
initi
locat
intens
treatment
patient
ill
tabl
pneumonia
port
predict
rule
deriv
inpati
cap
independ
valid
inpati
cap
inpati
outpati
prospect
enrol
pneumonia
port
cohort
studi
rule
patient
stratifi
sever
class
mean
process
step
patient
classifi
risk
class
lowest
sever
level
age
year
none
import
comorbid
condit
neoplast
diseas
liver
diseas
congest
heart
failur
cerebrovascular
diseas
renal
diseas
normal
mildli
derang
vital
sign
normal
mental
statu
step
patient
assign
risk
class
basi
initi
histori
physic
examin
find
alon
stratifi
class
iiv
basi
point
assign
demograph
variabl
age
sex
nurs
home
resid
comorbid
condit
list
physic
examin
find
alter
mental
statu
tachypnea
tachycardia
systol
hypotens
hypothermia
hyperthermia
laboratori
radiograph
find
acidemia
elev
blood
urea
nitrogen
hyponatremia
hyperglycemia
anemia
hypoxemia
pleural
effus
tabl
point
assign
correspond
follow
class
class
ii
class
iii
class
iv
class
v
deriv
valid
rule
mortal
low
risk
class
iiii
intermedi
class
iv
high
class
v
increas
risk
class
also
associ
subsequ
hospit
delay
return
usual
activ
outpati
rate
admiss
icu
length
stay
inpati
pneumonia
port
valid
cohort
basi
observ
pneumonia
port
investig
suggest
patient
risk
class
ii
gener
candid
outpati
treatment
risk
class
iii
patient
potenti
candid
outpati
treatment
brief
inpati
observ
patient
class
iv
v
hospit
tabl
estim
pneumonia
port
cohort
studi
suggest
recommend
would
reduc
proport
patient
receiv
tradit
inpati
care
would
brief
observ
inpati
stay
addit
effect
safeti
appli
pneumonia
port
predict
rule
initi
site
care
independ
popul
patient
cap
examin
use
modifi
version
pneumonia
port
predict
rule
emerg
room
physician
educ
rule
encourag
treat
risk
class
iiii
outpati
close
structur
followup
provis
oral
clarithromycin
cost
patient
desir
outcom
treat
home
intervent
phase
compar
outcom
histor
control
subject
time
period
immedi
preced
intervent
intervent
period
elig
patient
classifi
low
risk
shortterm
mortal
risk
class
iiii
comparison
control
subject
percentag
treat
initi
outpati
higher
intervent
period
control
period
vs
rel
increas
initi
plu
subp
p
sequent
hospit
use
outcom
measur
trend
toward
outpati
care
intervent
period
differ
longer
statist
signific
vs
none
initi
treat
p
p
outpati
set
intervent
period
die
within
week
present
second
multicent
control
trial
subsequ
assess
effect
safeti
use
pneumonia
port
predict
rule
initi
siteoftreat
decis
trial
emerg
depart
randomli
assign
either
continu
convent
manag
cap
implement
critic
pathway
includ
pneumonia
port
predict
rule
guid
admiss
decis
emerg
room
physician
educ
rule
encourag
treat
risk
class
iiii
outpati
oral
levofloxacin
overal
patient
cap
enrol
studi
use
predict
rule
result
reduct
admiss
lowrisk
patient
vs
use
rule
result
increas
morp
p
taliti
morbid
compromis
patient
function
statu
studi
support
use
pneumonia
port
predict
rule
help
physician
identifi
lowrisk
patient
safe
treat
outpati
set
idsa
panel
endors
find
pneumonia
port
predict
rule
identifi
valid
predictor
mortal
provid
ration
foundat
decis
regard
hospit
howev
emphas
port
predict
rule
valid
mortal
predict
model
method
triag
patient
cap
new
studi
requir
test
basic
premis
underli
use
rule
initi
siteoftreat
decis
patient
classifi
low
risk
treat
outpati
set
outcom
equival
better
similar
lowrisk
patient
hospit
import
note
predict
rule
meant
contribut
rather
supersed
physician
judgment
anoth
limit
factor
sever
ill
must
also
consid
determin
whether
individu
patient
candid
outpati
care
patient
design
low
risk
may
import
medic
psychosoci
contraind
outpati
care
includ
expect
complianc
problem
medic
treatment
poor
social
support
home
abil
maintain
oral
intak
histori
substanc
abus
cognit
impair
abil
perform
activ
daili
live
must
consid
addit
patient
may
rare
condit
sever
neuromuscular
diseas
immunosuppress
includ
predictor
predict
rule
increas
likelihood
poor
prognosi
predict
rule
may
also
oversimplifi
way
physician
interpret
import
predictor
variabl
exampl
extrem
alter
one
variabl
effect
risk
stratif
lesser
chang
despit
obviou
differ
clinic
import
eg
systol
blood
pressur
mm
hg
vs
one
mm
hg
furthermor
rule
discount
cumul
import
multipl
simultan
physiolog
derang
especi
derang
alon
reach
threshold
defin
abnorm
valu
eg
systol
blood
pressur
mm
hg
respiratori
rate
breath
min
puls
beatsmin
final
predict
rule
often
neglect
import
patient
prefer
clinic
decisionmak
point
highlight
observ
vast
major
lowrisk
patient
cap
prefer
site
care
solicit
despit
strong
prefer
outpati
care
prospect
studi
evalu
caus
cap
adult
fail
identifi
caus
case
cap
detect
etiolog
common
etiolog
agent
identifi
virtual
studi
cap
pneumonia
account
twothird
case
bacterem
pneumonia
case
pathogen
implic
less
frequent
includ
h
influenza
strain
nontyp
mycoplasma
pneumonia
c
pneumonia
aureu
streptococcu
pyogen
n
meningitidi
moraxella
catarrhali
klebsiella
pneumonia
gramneg
rod
legionella
speci
influenza
viru
depend
season
respiratori
syncyti
viru
adenoviru
parainfluenza
viru
microb
frequenc
etiolog
depend
specif
epidemiolog
factor
chlamydia
psittaci
psittacosi
coxiella
burnetii
q
fever
francisella
tularensi
tularemia
endem
fungi
histoplasmosi
blastomycosi
coccidioidomycosi
comparison
rel
frequenc
etiolog
pneumonia
hamper
vari
level
sensit
specif
test
use
pathogen
detect
exampl
studi
test
use
legionella
infect
provid
much
higher
degre
sensit
possibl
specif
test
use
pneumococc
infect
thu
rel
contribut
mani
caus
incid
cap
undoubtedli
either
exagger
underestim
depend
sensit
specif
test
use
studi
convinc
associ
demonstr
individu
symptom
physic
find
laboratori
test
result
specif
etiolog
even
timehonor
belief
absenc
product
cough
inflammatori
sputum
pneumonia
due
mycoplasma
legionella
chlamydia
speci
withstood
close
inspect
hand
comparison
involv
rel
small
number
patient
evalu
potenti
separ
caus
use
constel
symptom
physic
find
one
studi
yet
unconfirm
compar
patient
identifi
prospect
standard
fashion
score
system
use
symptom
laboratori
abnorm
abl
differenti
patient
legionnair
diseas
patient
similar
type
system
devis
identifi
patient
hantaviru
pulmonari
syndrom
hp
valid
score
system
may
use
identifi
patient
undergo
specif
diagnost
test
expens
use
routin
patient
cap
empir
treat
specif
antimicrobi
drug
test
result
pend
certain
pathogen
caus
pneumonia
commonli
among
person
specif
risk
factor
instanc
pneumococc
pneumonia
especi
like
occur
elderli
patient
varieti
medic
condit
includ
alcohol
chronic
cardiovascular
diseas
chronic
obstruct
airway
diseas
immunoglobulin
defici
hematolog
malign
hiv
infect
howev
outbreak
occur
among
young
adult
condit
crowd
armi
camp
prison
pneumonia
second
pneumocysti
carinii
common
identifi
caus
acut
pneumonia
patient
aid
legionella
opportunist
pathogen
legionella
pneumonia
rare
recogn
healthi
young
children
young
adult
import
caus
pneumonia
organ
transplant
recipi
patient
renal
failur
occur
increas
frequenc
patient
chronic
lung
diseas
smoker
possibl
aid
although
pneumonia
histor
thought
primarili
involv
children
young
adult
evid
suggest
caus
pneumonia
healthi
adult
age
season
differ
incid
mani
caus
cap
pneumonia
due
pneumonia
h
influenza
influenza
occur
predominantli
winter
month
wherea
c
pneumonia
appear
caus
pneumonia
yearround
although
summer
preval
outbreak
legionnair
diseas
sporad
case
occur
similar
frequenc
season
studi
suggest
season
variat
mycoplasma
infect
howev
data
suggest
incid
greatest
fall
winter
month
tabl
rational
establish
etiolog
diagnosi
permit
optim
antibiot
select
specif
direct
caus
agent
allow
ration
basi
chang
parenter
oral
therapi
chang
therapi
necessit
advers
drug
reaction
permit
antibiot
select
limit
consequ
injudici
antibiot
use
term
cost
patient
induc
resist
eg
induc
blactamas
advers
drug
reaction
improv
care
patient
advanc
knowledg
identifi
pathogen
potenti
epidemiolog
signific
legionella
hantaviru
penicillinresist
streptococcu
pneumonia
identifi
newli
emerg
pathogen
hantaviru
identifi
drugresist
pathogen
monitor
trend
drugresist
pneumonia
blactamaseproduc
haemophilu
influenza
methicillinresist
staphylococcu
aureu
prompt
contacttrac
antimicrobi
prophylaxi
neisseria
meningitidi
h
influenza
type
b
mycobacterium
tuberculosi
permit
antibiot
select
limit
effect
antibiot
overus
commun
cost
effici
averag
cost
standard
microbiolog
studi
averag
hospit
bill
narrowspectrum
agent
may
less
expens
although
mani
report
indic
yield
pathogen
expector
sputum
patient
cap
yield
may
often
increas
improv
techniqu
furthermor
neg
specimen
may
enhanc
probabl
atyp
agent
may
influenc
antimicrobi
choic
specimen
good
qualiti
show
yield
aureu
gramneg
bacilli
provid
good
evid
organ
present
inform
may
prove
use
patient
respond
convent
cultur
posttreat
specimen
rel
useless
tempor
variat
incid
caus
pneumonia
frequenc
sever
influenza
vari
result
antigen
drift
occasion
result
antigen
shift
less
clear
reason
increas
incid
mycoplasma
infect
occur
everi
year
yeartoyear
variat
may
also
occur
pneumococc
pneumonia
littl
known
geograph
differ
incid
pneumonia
surveil
data
cdc
suggest
legionnair
diseas
occur
highest
incid
northeastern
state
state
great
lake
area
howev
differ
ascertain
diseas
may
contribut
factor
incid
pneumonia
due
pathogen
environment
relat
would
expect
vari
chang
relev
environment
condit
exampl
incid
legionnair
diseas
depend
presenc
pathogen
legionella
speci
water
amplif
bacteria
reservoir
ideal
nutrit
milieu
use
aerosolproduc
devic
spread
contamin
water
via
aerosol
droplet
ideal
meteorolog
condit
transport
aerosol
suscept
host
presenc
suscept
host
alter
variabl
would
probabl
lead
variat
incid
likewis
increas
rainfal
associ
increas
rodent
popul
hypothes
basi
epidem
hp
southwestern
unit
state
pneumonia
suspect
patient
newli
acquir
lower
respiratori
symptom
cough
sputum
product
andor
dyspnea
especi
accompani
fever
alter
breath
sound
rale
recogn
must
balanc
reason
diagnost
test
tabl
empir
therapi
import
establish
diagnosi
pneumonia
caus
heighten
increas
concern
antibiot
overus
diagnosi
cap
base
combin
clinic
laboratori
includ
microbiolog
data
differenti
diagnosi
lower
respiratori
symptom
extens
includ
upper
lower
respiratori
tract
infect
well
noninfecti
caus
eg
reactiv
airway
diseas
atelectasi
congest
heart
failur
bronchiol
obliteran
organ
pneumonia
boop
vascul
pulmonari
embol
pulmonari
malign
case
upper
respiratori
tract
infect
ab
viral
origin
requir
antimicrobi
therapi
sourc
great
antibiot
abus
contrast
antimicrobi
therapi
usual
indic
pneumonia
chest
radiographi
usual
necessari
establish
diagnosi
pneumonia
physic
examin
detect
rale
bronchial
breath
sound
neither
sensit
specif
detect
pneumonia
chest
radiographi
consid
sensit
occasion
use
determin
etiolog
diagnosi
prognosi
altern
diagnos
associ
condit
chest
radiograph
patient
p
carinii
pneumonia
pcp
falseneg
patient
except
relev
immunocompet
adult
host
one
studi
show
spiral
ct
scan
significantli
sensit
detect
pulmonari
infiltr
clinic
signific
result
unclear
idsa
panel
endors
routin
use
technolog
preliminari
natur
data
high
cost
procedur
time
limit
resourc
may
seem
attract
treat
patient
cap
basi
present
manifest
without
radiograph
confirm
approach
discourag
given
cost
potenti
danger
antimicrobi
abus
term
side
effect
resist
inde
preval
pneumonia
among
adult
respiratori
symptom
suggest
pneumon
rang
gener
outpati
set
emerg
depart
idsa
panel
recommend
chest
radiographi
includ
routin
evalu
patient
pneumonia
consid
like
diagnosi
aii
emphasi
microbiolog
studi
gram
stain
cultur
expector
sputum
idsa
guidelin
repres
differ
guidelin
american
thorac
societi
argument
microbiolog
studi
includ
low
yield
mani
report
lack
document
benefit
term
cost
outcom
concern
idsa
panel
member
percept
qualiti
microbiolog
technolog
appli
respiratori
secret
deterior
substanti
compar
earlier
era
furthermor
percept
regul
clinic
laboratori
improv
act
discourag
physician
examin
sputum
sampl
microscop
contribut
declin
although
data
clearli
demonstr
costeffect
advantag
attempt
identifi
pathogen
studi
specif
design
address
issu
report
rational
preserv
microbiolog
immunolog
test
summar
tabl
classifi
advantag
regard
individu
patient
societi
cost
desir
identifi
etiolog
agent
heighten
concern
empir
select
drug
increas
microbi
resist
unnecessari
cost
avoid
side
effect
addit
work
prior
investig
microbiolog
find
provid
rational
consid
essenti
creation
guidelin
base
probabl
etiolog
agent
detail
histori
may
help
suggest
diagnosi
epidemiolog
clue
may
lead
diagnost
consider
list
tabl
certain
find
histor
identifi
clue
specif
caus
pneumonia
although
confin
control
studi
acut
onset
singl
episod
shake
chill
rigor
pleurisi
suggest
pneumococc
infect
prodrom
fever
myalgia
follow
pulmonari
edema
hypotens
characterist
hp
underli
copd
often
seen
pneumonia
due
h
influenza
catarrhali
separ
togeth
pneumonia
putrid
sputum
indic
infect
caus
anaerob
bacteria
although
mani
studi
cap
found
clinic
featur
often
distinguish
etiolog
agent
other
support
util
clinic
clue
support
etiolog
diagnosi
clinic
diagnosi
cap
made
consider
given
microbiolog
diagnosi
bacteriolog
studi
sputum
blood
practic
standard
collect
transport
process
respiratori
secret
detect
common
bacteri
pathogen
summar
tabl
mani
pathogen
requir
special
test
detect
summar
tabl
rapid
tabl
recommend
expector
sputum
collect
transport
process
specimen
obtain
deep
cough
gross
purul
obtain
treatment
antimicrobi
agent
presenc
health
care
provid
specimen
immedi
transport
laboratori
prompt
process
purul
portion
select
gram
stain
cultur
quellung
stain
done
avail
cytolog
screen
done
lowpow
magnif
determin
cellular
composit
see
text
diagnost
evalu
etiolog
cytolog
assess
necessari
screen
specimen
detect
respiratori
virus
legionella
speci
mycobacteria
cultur
perform
use
standard
techniqu
result
report
semiquantit
assess
pathogen
recov
growth
indic
coloni
second
quadrant
diagnost
test
routin
use
gram
stain
respiratori
secret
usual
expector
sputum
other
includ
direct
fluoresc
antibodi
dfa
stain
sputum
urinari
antigen
assay
legionella
use
select
case
urinari
antigen
assay
pneumonia
acidfast
bacilli
afb
stain
detect
mycobacteri
infect
sever
test
influenza
mani
rapid
diagnost
test
pcr
earli
develop
commonli
avail
suffici
reliabl
pcr
test
detect
mycobacterium
tuberculosi
pcr
test
detect
respiratori
tract
pathogen
clear
us
food
drug
administr
fda
recommend
use
specimen
contain
afb
direct
smear
diagnost
procedur
provid
identif
specif
etiolog
within
h
still
use
guid
continu
therapi
etiolog
diagnosi
use
prognost
therapeut
purpos
diagnosi
establish
failur
respond
treatment
dealt
logic
fashion
base
caus
organ
document
antibiot
suscept
rather
empir
select
antimicrobi
agent
broader
differ
spectrum
furthermor
drug
reaction
develop
appropri
substitut
readili
select
perform
blood
cultur
within
h
admiss
cap
associ
signific
reduct
mortal
regard
sputum
bacteriolog
sever
studi
suggest
mortal
associ
cap
hospit
patient
without
etiolog
diagnosi
studi
specif
design
test
hypothesi
instead
conclus
base
retrospect
analys
case
without
etiolog
diagnosi
outcom
also
interest
assess
length
stay
cost
resourc
use
morbid
studi
although
uncontrol
suggest
benefit
diagnost
studi
exampl
boerner
zwadyk
report
posit
earli
diagnosi
sputum
gram
stain
correl
rapid
resolut
fever
initi
antimicrobi
therapi
addit
studi
torr
et
al
show
inadequ
antibiot
treatment
clearli
relat
poor
outcom
suggest
establish
etiolog
diagnosi
import
frequenc
microbiolog
studi
cap
patient
highli
variabl
report
pneumonia
port
studi
analysi
hospit
patient
show
frequenc
sputum
gram
stain
sputum
cultur
within
h
admiss
respect
studi
done
outpati
cap
particip
center
publish
studi
cap
academ
institut
microbiolog
studi
probabl
frequent
health
care
set
find
like
pathogen
blood
cultur
averag
publish
report
concern
hospit
patient
cap
yield
sputum
studi
highli
variabl
rang
hospit
patient
usual
outpati
larg
variat
among
studi
presum
explain
variat
qualiti
microbiolog
analys
epidemiolog
pattern
patient
popul
serv
consensu
establish
etiolog
diagnosi
perform
blood
cultur
initi
antimicrobi
treatment
ai
sputum
gram
stain
cultur
bii
valu
patient
requir
hospit
goal
establish
specif
diagnosi
use
precis
often
costeffect
use
antimicrobi
agent
hand
util
diagnost
studi
cap
less
sever
requir
hospit
unclear
studi
need
verifi
signific
diagnost
studi
case
etiolog
diagnosi
confid
accuraci
diagnosi
depend
pathogen
diagnost
test
follow
diagnosi
definit
definit
etiolog
establish
compat
clinic
syndrom
plu
recoveri
probabl
etiolog
agent
uncontamin
specimen
blood
pleural
fluid
transtrach
aspir
transthorac
aspir
recoveri
respiratori
secret
like
pathogen
colon
upper
airway
eg
tuberculosi
legionella
speci
influenza
viru
p
carinii
tabl
ai
serolog
test
regard
diagnost
although
result
usual
avail
time
manner
diagnost
criteria
controversi
diagnosi
probabl
probabl
etiolog
diagnosi
establish
compat
clinic
syndrom
detect
stain
cultur
like
pulmonari
pathogen
respiratori
secret
expector
sputum
bronchoscop
aspir
quantit
cultur
bronchoscop
bronchoalveolar
lavag
bal
fluid
brush
cathet
specimen
semiquantit
cultur
pathogen
recov
moder
heavi
growth
bii
test
specimen
use
etiolog
diagnosi
follow
test
type
specimen
use
establish
etiolog
diagnosi
bodi
fluid
blood
cultur
specimen
needlestick
perform
separ
site
obtain
patient
requir
hospit
acut
pneumonia
ai
potenti
infect
bodi
fluid
anatom
site
includ
pleural
fluid
joint
fluid
csf
gram
stain
cultur
warrant
clinic
present
sputum
examin
tabl
figur
valu
gram
stain
expector
sputum
debat
recommend
rel
simpl
inexpens
procedur
guid
initi
select
antimicrobi
therapi
provid
deepcough
specimen
obtain
antibiot
therapi
rapidli
transport
properli
process
laboratori
within
hour
collect
bii
therapi
antimicrobi
agent
delay
acut
ill
patient
difficulti
obtain
specimen
microbiolog
studi
routin
laboratori
test
includ
gram
stain
cytolog
screen
aerob
cultur
specimen
satisfi
cytolog
criteria
cytolog
criteria
judg
accept
specimen
includ
rel
number
polymorphonuclear
cell
pmn
squamou
epitheli
cell
sec
patient
normal
elev
wbc
count
determin
use
lowpowerfield
examin
lpf
accept
valu
rang
seclpf
seclpf
base
correl
cultur
result
clinic
find
result
transtrach
aspir
ai
author
recommend
criterion
wbc
per
sec
mycobacteria
legionella
speci
except
sinc
microscop
criteria
may
yield
mislead
result
cultur
perform
rapidli
although
consequ
time
delay
process
disput
interpret
expector
sputum
cultur
includ
clinic
correl
semiquantit
result
offic
practic
may
realist
perform
gram
stain
time
manner
guid
antibiot
decis
slide
may
prepar
airdri
heatfix
subsequ
interpret
ciii
numer
studi
support
use
routin
microscop
examin
gramstain
sputum
sampl
recognit
lancetshap
gramposit
diplococci
suggest
pneumonia
show
sensit
sputum
gram
stain
patient
pneumococc
pneumonia
specif
prospect
studi
patient
admit
hospit
cap
valid
specimen
obtain
cytolog
criteria
pmn
sec
evid
lowpow
magnif
gramstain
smear
valid
specimen
criteria
show
predomin
bacteri
morphotyp
predict
blood
cultur
isol
valid
specimen
physician
could
select
appropri
antimicrobi
therapi
patient
basi
gramstain
result
haemophilu
pneumonia
gram
stain
read
even
reliabl
profus
number
organ
regularli
present
find
mani
wbc
bacteria
patient
alreadi
receiv
antibiot
reliabl
exclud
infect
ordinari
bacteri
pathogen
valid
gramstain
read
howev
directli
relat
experi
interpret
routin
cultur
expector
sputum
neither
sensit
specif
common
bacteriolog
method
mani
laboratori
use
like
explan
unreli
microbiolog
data
specimen
provid
rich
enough
sourc
inflammatori
materi
lower
respiratori
tract
either
patient
unabl
cough
reliabl
specimen
health
care
provid
give
suffici
prioriti
obtain
specimen
reason
includ
prior
administr
antibiot
delay
process
specimen
insuffici
attent
separ
sputum
saliva
streak
slide
cultur
plate
difficulti
interpret
contamin
flora
upper
airway
flora
may
includ
potenti
pathogen
lead
falseposit
cultur
normal
flora
often
overgrow
true
pathogen
lead
falseneg
cultur
especi
fastidi
pathogen
pneumonia
case
bacterem
pneumococc
pneumonia
pneumonia
may
isol
sputum
cultur
case
standard
microbiolog
techniqu
use
yield
pneumonia
substanti
higher
transtrach
aspir
transthorac
needl
aspir
quantit
cultur
bal
aspir
prior
antibiot
therapi
may
reduc
yield
common
respiratori
pathogen
cultur
respiratori
tract
specimen
sourc
often
associ
falseposit
cultur
upper
airway
contamin
gramneg
bacilli
aureu
induc
sputum
util
specimen
detect
pulmonari
pathogen
p
carinii
tuberculosi
poorli
establish
serolog
studi
test
usual
help
initi
evalu
patient
cap
ciii
may
provid
data
use
epidemiolog
surveil
cold
agglutinin
titer
support
diagnosi
pneumonia
infect
sensit
test
poor
specif
igm
antibodi
pneumonia
requir
week
reach
diagnost
titer
report
result
sensit
variabl
serolog
respons
chlamydia
legionella
speci
take
even
longer
acut
antibodi
test
legionella
legionnair
diseas
usual
neg
demonstr
low
titer
author
accept
acut
titer
criterion
probabl
presumpt
diagnosi
studi
show
titer
posit
predict
valu
serolog
test
use
acutephas
serum
specimen
must
obtain
select
patient
etiolog
case
remain
question
convalescentphas
serum
obtain
serolog
studi
pair
sera
perform
method
identifi
caus
agent
primarili
epidemiolog
inform
data
indic
commonli
avail
serolog
test
use
accur
guid
therapi
acut
infect
caus
pneumonia
c
pneumonia
legionella
diii
antigen
detect
antigendetect
method
identif
microorgan
sputum
fluid
studi
year
varieti
techniquescounterimmunoelectrophoresi
latex
agglutin
immunofluoresc
enzym
immunoassay
eia
although
use
identif
bacteri
agent
ie
pneumonia
favor
mani
european
center
less
accept
north
american
laboratori
cost
time
requir
rel
lack
sensit
specif
depend
method
potenti
limit
fda
recent
approv
immunochromatograph
membran
assay
detect
pneumonia
antigen
urin
result
may
obtain
quickli
min
initi
test
accord
packag
insert
test
sensit
specif
disadvantag
limit
experi
assay
need
cultur
order
determin
suscept
guid
therapi
lack
publish
data
perform
characterist
idsa
panel
endors
test
complement
sputum
blood
cultur
ciii
quellung
test
also
rapid
assay
detect
pneumonia
requir
adequ
expertis
rapid
commerci
avail
eia
avail
detect
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
virus
sensit
test
rapid
method
detect
influenza
viru
special
interest
avail
antivir
agent
must
given
within
h
onset
symptom
test
show
sensit
specif
clinic
detect
influenza
basi
typic
symptom
influenza
epidem
appear
sensit
urinari
antigen
test
shown
sensit
specif
detect
l
pneumophila
serogroup
account
report
legionella
case
unit
state
possibl
advantag
technic
eas
test
perform
valid
result
sever
day
effect
antibiot
treatment
dfa
stain
respiratori
secret
technic
demand
show
optim
result
l
pneumophila
show
poor
sensit
specif
perform
expert
use
certain
antibodi
cultur
urin
antigen
test
show
sensit
specif
neg
laboratori
test
exclud
legionella
particularli
case
caus
organ
l
pneumophila
serogroup
posit
cultur
urin
antigen
assay
virtual
diagnost
idsa
panel
recommend
urinari
antigen
assay
sputum
cultur
select
nonselect
media
specimen
decontamin
plate
detect
legionnair
diseas
aii
dna
probe
amplif
sever
rapid
diagnost
test
use
nucleic
acid
amplif
evalu
respiratori
secret
serum
present
develop
especi
chlamydia
mycoplasma
legionella
reagent
test
clear
fda
avail
gener
restrict
research
refer
laboratori
test
becom
avail
may
help
establish
earli
diagnosi
allow
direct
therapi
time
care
greatest
potenti
util
anticip
detect
pneumonia
legionella
select
pathogen
infrequ
colon
upper
airway
absenc
diseas
tabl
invas
diagnost
test
transtrach
aspir
bronchoscopi
percutan
lung
aspir
tabl
transtrach
aspir
previous
use
obtain
uncontamin
lower
respiratori
secret
valid
cultur
detect
anaerob
organ
well
common
aerob
pathogen
procedur
infrequ
perform
concern
advers
effect
lack
personnel
skill
techniqu
consequ
reduc
use
transtrach
aspir
lack
method
detect
anaerob
bacteria
lung
absenc
empyema
bacteremia
util
fiberopt
bronchoscopi
variabl
depend
pathogen
techniqu
aspir
inner
channel
bronchoscop
subject
contamin
upper
airway
flora
cultur
anaerob
sinc
limit
expector
sputum
recoveri
common
bacteri
pathogen
quantit
cultur
bal
protectedbrush
cathet
specimen
consid
superior
techniqu
collect
transport
process
specimen
quantit
cultur
avail
publish
sourc
bronchoscopi
impract
routin
use
expens
requir
technic
expertis
may
difficult
perform
time
manner
author
favor
use
patient
fulmin
cours
requir
admiss
icu
complex
pneumonia
unrespons
antimicrobi
therapi
bronchoscopi
especi
use
detect
select
pathogen
p
carinii
mycobacterium
speci
cytomegaloviru
idsa
panel
recommend
blood
cultur
expector
sputum
gram
stain
cultur
microbiolog
studi
consid
routin
patient
hospit
cap
transtrach
aspir
transthorac
needl
aspir
bronchoscopi
reserv
select
patient
use
appropri
expertis
biii
regard
recommend
diagnost
approach
tabl
list
diagnost
studi
recommend
hospit
patient
accord
sever
ill
bii
pneumonia
among
lead
infecti
caus
ill
death
worldwid
young
children
person
underli
chronic
system
condit
elderli
metaanalysi
report
cap
englishlanguag
literatur
show
pneumonia
account
twothird
case
etiolog
diagnosi
made
well
twothird
case
lethal
pneumonia
unit
state
estim
case
pneumococc
pneumonia
necessit
hospit
year
vaccin
common
serotyp
pneumonia
avail
advisori
committe
immun
practic
recommend
vaccin
administ
person
age
year
younger
patient
underli
medic
condit
associ
increas
risk
pneumococc
diseas
complic
revaccin
recommend
year
recent
unit
state
pneumonia
nearli
uniformli
suscept
penicillin
allow
clinician
treat
patient
sever
pneumococc
infect
penicillin
g
alon
nearli
commonli
use
antibiot
without
test
drug
suscept
resist
pneumonia
penicillin
antimicrobi
drug
first
note
australia
papua
new
guinea
found
major
problem
south
africa
subsequ
mani
countri
europ
africa
asia
unit
state
nonsuscept
penicillin
increas
markedli
last
decad
appear
continu
suscept
pneumonia
penicillin
current
defin
nation
committe
clinic
laboratori
standard
nccl
follow
suscept
isol
inhibit
mgml
ie
mic
mgml
isol
reduc
suscept
also
known
intermedi
resist
inhibit
mgml
resist
isol
mgml
amoxicillin
effect
penicillin
pneumococci
vitro
mic
threshold
higher
import
problem
definit
clinic
point
view
mic
entir
differ
mean
depend
infect
treat
strain
reduc
suscept
eg
mic
mgml
behav
suscept
organ
caus
pneumonia
see
probabl
caus
mening
basi
present
definit
depend
sourc
isol
june
unit
state
pneumonia
isol
infect
person
intermedi
resist
resist
penicillin
variat
occur
citi
citi
within
segment
popul
even
within
institut
singl
citi
actual
result
vari
greatli
depend
sourc
isol
nccl
definit
base
level
achiev
csf
case
mening
much
higher
level
achiev
blood
alveoli
reason
treat
pneumonia
gener
accept
dose
penicillin
intermedi
resist
clinic
import
resist
may
import
especi
highgrad
eg
mic
mgml
rate
resist
substanti
higher
mani
european
countri
unit
state
notabl
except
netherland
germani
countri
accept
standard
practic
strictli
limit
antibiot
usag
especi
among
young
children
resist
penicillin
one
small
part
pictur
although
major
strain
reduc
suscept
penicillin
suscept
certain
thirdgener
cephalosporin
cefotaxim
ceftriaxon
defin
mic
mgml
intermedi
resist
drug
mic
mgml
resist
mic
mgml
increas
accord
definit
onehalf
strain
reduc
penicillin
suscept
also
reduc
suscept
cephalosporin
tabl
greater
proport
exhibit
resist
thirdgener
secondgener
cephalosporin
case
penicillin
pneumonia
caus
intermedi
resist
even
resist
isol
like
respond
treatment
standard
dose
cefotaxim
ceftriaxon
cefuroxim
less
activ
pneumonia
activ
cephalosporin
predict
result
vitro
suscept
test
cefotaxim
ceftriaxon
import
resist
extend
far
beyond
blactam
antibiot
although
genet
pneumococc
resist
complex
blactamresist
organ
often
acquir
gene
confer
resist
class
antimicrobi
transform
conjug
transposon
thu
pneumococci
penicillinresist
also
often
resist
antibiot
appropri
term
character
multipli
antibioticresist
tabl
data
reflect
gener
situat
unit
state
octob
resist
antimicrobi
overcom
increas
dose
antibiot
macrolid
exampl
unit
state
macrolid
resist
result
increas
drug
efflux
encod
mefe
erythromycin
mic
mgml
suscept
clindamycin
possibl
resist
may
overcom
achiev
level
macrolid
europ
macrolid
resist
due
ribosom
methylas
encod
ermam
result
highgrad
resist
macrolid
resist
clindamycin
probabl
overcom
import
emphas
resist
newer
macrolid
azithromycin
clarithromycin
parallel
resist
erythromycin
preval
resist
tetracyclin
among
pneumococci
similar
resist
macrolid
resist
trimethoprimsulfamethoxazol
tmpsmz
far
preval
use
combin
discourag
among
fdaapprov
drug
vancomycin
linezolid
current
effect
essenti
pneumococci
fluoroquinolon
activ
strain
includ
penicillinresist
strain
resist
drug
begun
increas
area
use
extens
newer
drug
oxazolidinon
glycopeptid
appear
promis
mic
drugresist
pneumonia
higher
penicillinsuscept
strain
resist
streptogramin
appear
parallel
macrolid
studi
oral
outpati
therapi
pneumonia
major
case
probabl
due
pneumonia
shown
good
outcom
regardless
therapi
given
howev
studi
design
examin
antibiot
resist
among
pneumococci
recommend
antimicrobi
agent
empir
treatment
pneumococc
pneumonia
includ
amoxicillin
mg
thrice
daili
cefuroxim
axetil
mg
twice
daili
cefpodoxim
mg
twice
daili
cefprozil
mg
twice
daili
azithromycin
clarithromycin
erythromycin
quinolon
doxycyclin
ordinarili
prescrib
dosag
amoxicillin
prefer
penicillin
reliabl
absorpt
longer
halflif
slightli
favor
mic
although
recent
surveil
studi
indic
increas
resist
macrolid
date
pauciti
report
clinic
failur
patient
without
risk
factor
infect
drugresist
pneumonia
increas
use
howev
concern
reduc
efficaci
macrolid
hospit
patient
pneumococc
pneumonia
caus
organ
suscept
intermedi
resist
penicillin
respond
treatment
penicillin
million
unit
everi
h
ampicillin
g
everi
h
cefotaxim
g
everi
h
ceftriaxon
g
everi
h
pneumonia
due
penicillinor
cephalosporinresist
organ
probabl
requir
higher
dose
drug
retrospect
studi
shown
similar
outcom
treatment
standard
dose
penicillin
cephalosporin
without
regard
whether
pneumonia
due
suscept
nonsuscept
organ
number
subject
infect
resist
pneumococci
mic
mgml
small
trend
toward
wors
outcom
studi
cdc
studi
found
mortal
associ
treat
pneumococc
pneumonia
increas
condit
due
penicillinresist
pneumococci
due
ceftriaxoneresist
pneumococci
even
adjust
sever
underli
ill
previou
hospit
increas
likelihood
resist
pneumococci
present
studi
howev
determin
natur
treatment
case
seem
like
ultim
penicillin
ceftriaxon
may
reliabl
cure
infect
caus
strain
pneumonia
penicillin
mic
mgml
ceftriaxon
mic
mgml
present
mani
author
treat
pneumococc
pneumonia
even
critic
ill
patient
cefotaxim
g
everi
h
ceftriaxon
g
everi
h
mani
patient
receiv
g
ampicillin
without
sulbactam
everi
h
good
respons
although
vancomycin
nearli
certain
provid
antibiot
coverag
strong
impetu
use
drug
proven
need
fear
emerg
resist
organ
vancomycin
fluoroquinolon
use
initi
treatment
pneumococc
pneumonia
critic
ill
patient
allerg
blactam
antibiot
quinupristindalfopristin
linezolid
op
tion
experi
antimicrobi
agent
pneumococc
pneumonia
extrem
limit
aspir
pneumonia
broadli
defin
pulmonari
sequela
abnorm
entri
materi
stomach
upper
respiratori
tract
lower
airway
term
gener
appli
largevolum
aspir
least
distinct
form
base
natur
inoculum
clinic
present
manag
guidelin
toxic
injuri
lung
due
gastric
acid
aspir
mendelson
syndrom
obstruct
foreign
bodi
fluid
infect
tabl
syndrom
review
elsewher
studi
show
aspir
suspect
patient
hospit
cap
although
criteria
diagnosi
often
provid
gener
diagnosi
suspect
patient
condit
predispos
aspir
usual
compromis
conscious
dysphagia
radiograph
evid
involv
depend
pulmonari
segment
lower
lobe
depend
upright
posit
superior
segment
lower
lobe
posterior
segment
upper
lobe
depend
recumb
posit
aspir
pneumonia
presum
caus
nearli
case
anaerob
pulmonari
infect
microaerophil
anaerob
mouth
flora
anticip
pathogen
bacteri
infect
associ
aspir
frequenc
infect
involv
anaerob
among
patient
cap
known
method
requir
obtain
uncontamin
specimen
valid
anaerob
cultur
rare
use
usual
specimen
transtrach
aspir
pleural
fluid
transthorac
needl
aspir
uncontamin
specimen
metastat
site
limit
experi
suggest
quantit
cultur
protectedbrush
bal
specimen
collect
bronchoscopi
may
accept
anaerob
microaerophil
bacteria
common
etiolog
agent
lung
abscess
aspir
pneumonia
rel
common
isol
empyema
characterist
mani
bacteri
speci
isol
infect
tissu
patient
anaerob
bacteri
infect
may
also
present
pneumon
indistinguish
common
form
bacteri
pneumonia
basi
clinic
featur
clinic
clue
diagnosi
includ
predisposit
aspir
infect
gingiv
crevic
gingiv
putrid
discharg
necrosi
tissu
abscess
format
bronchopulmonari
fistula
infect
complic
airway
obstruct
chronic
cours
infect
depend
pulmonari
segment
anaerob
may
also
account
substanti
number
case
cap
characterist
featur
regard
therapi
compar
therapeut
trial
anaerob
lung
infect
lung
abscess
show
clindamycin
superior
iv
penicillin
use
metronidazol
alson
antimicrobi
therapi
associ
high
failur
rate
presum
role
play
facult
microaerophil
streptococci
amoxicillinclavulan
ai
also
appear
effect
antibiot
virtual
alway
activ
anaerob
vitro
includ
imipenem
meropenem
metronidazol
chloramphenicol
combin
blactam
blactamas
inhibitor
moxifloxacin
gatifloxacin
trovafloxacin
also
good
vitro
activ
anaerob
macrolid
cephalosporin
doxycyclin
variabl
activ
tmpsmz
aminoglycosid
activ
anaerob
idsa
panel
recommend
clindamycin
blactam
blactamas
inhibitor
imipenem
meropenem
prefer
drug
treat
pulmonari
infect
anaerob
bacteria
establish
suspect
caus
bi
although
preval
vari
year
year
within
geograph
set
c
pneumonia
caus
case
cap
major
case
pneumonia
rel
mild
associ
low
mortal
c
pneumonia
pneumonia
may
present
sore
throat
hoars
headach
import
nonpneumon
symptom
find
includ
sinus
reactiv
airway
diseas
empyema
reinfect
common
hospit
due
pneumonia
caus
c
pneumonia
usual
occur
older
patient
reinfect
comorbid
undoubtedli
play
signific
role
clinic
cours
c
pneumonia
found
associ
pathogen
particularli
pneumonia
associ
pathogen
appear
determin
clinic
cours
pneumonia
infect
suspect
cultur
c
pneumonia
dna
detect
pcr
serolog
specif
microimmunofluoresc
antibodi
howev
cell
cultur
routin
avail
except
research
laboratori
addit
pcr
technolog
standard
reagent
pcr
fda
clear
serolog
problemat
nonspecif
prefer
diagnost
find
document
increas
titer
acut
convalesc
specimen
support
evid
pcr
cultur
accordingli
laboratori
confirm
diagnosi
c
pneumonia
pneumonia
time
fashion
treatment
must
empir
aii
therapi
idsa
panel
recommend
macrolid
doxycyclin
fluoroquinolon
bii
legionella
implic
cap
case
hospitalbas
seri
group
report
higher
rate
presum
reflect
local
epidemiolog
andor
sensit
laboratori
techniqu
risk
relat
exposur
increas
age
smoke
compromis
cellmedi
immun
transplant
recipi
although
rare
immunocompet
adult
age
year
legionella
major
caus
lethal
pneumonia
mortal
rate
among
immunocompet
host
substanti
higher
rate
among
immunosuppress
host
test
commonli
cost
routin
use
hospit
patient
usual
advoc
tabl
major
indic
test
includ
sever
ill
adult
requir
admiss
icu
pneumonia
hospit
patient
like
etiolog
ie
neg
gram
stain
pneumonia
compromis
host
evid
suggest
legionella
endem
epidem
area
lack
respons
blactam
antibiot
clinic
featur
suggest
legionella
caus
ciii
epidemiolog
risk
factor
legionnair
diseas
includ
recent
travel
overnight
stay
outsid
home
recent
chang
domest
plumb
renal
hepat
failur
diabet
system
malign
author
feel
follow
constel
clinic
featur
suggest
diagnosi
high
fever
hyponatremia
cn
manifest
lactat
dehydrogenas
level
unitsml
sever
diseas
method
laboratori
detect
includ
cultur
serolog
dfa
stain
urinari
antigen
assay
pcr
dfa
stain
requir
substanti
expertis
interpret
select
reagent
critic
pcr
expens
fdaclear
reagent
test
recommend
idsa
panel
urinari
antigen
assay
l
pneumophila
serogroup
technic
demand
reliabl
rapidli
detect
case
legionnair
diseas
cultur
select
media
detect
strain
technic
demand
bii
histor
prefer
therapeut
agent
erythromycin
usual
total
daili
dose
g
iv
without
rifampin
mg
po
qd
erythromycin
mg
po
qid
complet
week
treatment
substitut
clinic
respons
mani
author
consid
azithromycin
fluoroquinolon
prefer
sever
diseas
prefer
base
result
superior
erythromycin
anim
model
addit
poor
toler
erythromycin
fdaapprov
drug
administr
legionella
erythromycin
azithromycin
ciprofloxacin
ofloxacin
levofloxacin
trovafloxacin
gatifloxacin
delay
therapi
associ
increas
mortal
idsa
panel
consid
doxycyclin
azithromycin
ofloxacin
ciprofloxacin
levofloxacin
prefer
legionnair
diseas
basi
avail
data
bii
drug
avail
oral
parenter
administr
durat
treatment
day
although
less
azithromycin
long
halflif
hp
frequent
lethal
system
diseas
previous
healthi
young
adult
origin
recogn
may
least
virus
implic
common
unit
state
sin
nombr
viru
carri
deer
mous
case
hp
report
nearli
everi
region
unit
state
case
found
four
corner
area
new
mexico
arizona
utah
colorado
median
age
patient
first
unit
state
case
year
overal
case
fatal
rate
common
featur
prodrom
phase
includ
fever
chill
myalgia
headach
nausea
vomit
andor
diarrhea
cough
common
promin
earli
featur
initi
symptom
resembl
common
viral
infect
characterist
featur
often
becom
evid
day
prodrom
includ
characterist
laboratori
chang
chest
radiograph
evid
capillari
leakag
adult
respiratori
distress
syndrom
ard
oxygen
desatur
common
caus
ard
consider
chronic
pulmonari
diseas
malign
trauma
burn
surgeri
among
lethal
case
hp
median
time
death
day
onset
diseas
typic
laboratori
find
includ
hemoconcentr
thrombocytopenia
leukocytosi
left
shift
circul
immunoblast
addit
laboratori
find
includ
elev
serum
lactat
dehydrogenas
level
arteri
partial
pressur
oxygen
mm
hg
increas
serum
lactat
level
diagnosi
establish
detect
hantavirusspecif
igm
increas
titer
hantavirusspecif
igg
hantavirusspecif
rna
pcr
clinic
specimen
hantaviru
antigen
immunohistochemistri
laboratori
test
perform
confirm
refer
laboratori
treatment
consist
support
care
often
requir
intub
mechan
ventil
posit
endexpiratori
pressur
patient
also
requir
hemodynam
support
ribavirin
inhibit
sin
nombr
viru
vitro
initi
clinic
experi
disappoint
control
trial
ongo
pneumonia
common
caus
respiratori
tract
infect
primarili
age
year
young
adult
organ
caus
small
percentag
case
cap
requir
hospit
incub
period
week
epidem
close
popul
evolv
slowli
common
present
tracheobronch
patient
acut
infect
mycoplasma
pneumonia
demonstr
chest
radiographi
common
symptom
pneumonia
includ
prodrom
period
fever
chill
headach
sore
throat
follow
cough
dri
produc
mucoid
sputum
cough
frequent
sever
night
may
persist
week
possibl
clue
diagnosi
histori
contact
person
similar
condit
character
long
incub
period
extrapulmonari
manifest
may
includ
cold
hemagglutin
hemolyt
anemia
nausea
vomit
rare
myocard
skin
rash
divers
neurolog
syndrom
laboratori
test
confirm
infect
due
pneumonia
includ
cultur
serolog
pcr
fastidi
growth
requir
long
incub
period
limit
util
cultur
laboratori
offer
test
igm
igg
antibodi
valu
becom
elev
case
respons
often
delay
util
test
earli
detect
limit
report
result
variabl
author
consid
pcr
particularli
promis
current
problem
amplif
techniqu
includ
great
variabl
due
differ
method
sampl
collect
sampl
prepar
amplif
procedur
also
fdaclear
reagent
pcr
detect
mycoplasma
cold
agglutinin
titer
support
diagnosi
cold
agglutinin
respons
correl
sever
pulmonari
symptom
test
lack
sensit
specif
suggest
singl
cf
antibodi
titer
combin
cold
agglutinin
titer
support
diagnosi
antibodi
respons
usual
develop
day
onset
symptom
show
peak
level
week
chang
chest
radiographi
nonspecif
common
unilater
infiltr
onethird
patient
bilater
chang
idsa
panel
conclud
avail
diagnost
test
reliabl
rapidli
detect
pneumonia
thu
therapi
must
usual
empir
bii
panel
recommend
treatment
tetracyclin
macrolid
case
altern
fluoroquinolon
biii
treatment
given
week
reduc
risk
relaps
role
antibiot
therapi
extrapulmonari
manifest
establish
pcp
includ
guidelin
manag
cap
immunocompet
host
seen
exclus
patient
defect
cellmedi
immun
nevertheless
rel
common
import
form
pneumonia
especi
patient
hiv
infect
may
still
unawar
underli
infect
one
studi
consecut
hospit
cap
urban
hospit
show
patient
hiv
infect
patient
unawar
hiv
statu
time
admiss
point
emphas
pcp
common
initi
aidsdefin
diagnosi
suspect
select
patient
even
absenc
known
immunodefici
characterist
clinic
featur
pcp
includ
nonproduct
cough
fever
dyspnea
evolv
period
week
averag
patient
pulmonari
symptom
week
time
initi
present
rel
slow
tempo
diseas
distinguish
pcp
patient
aid
common
form
bacteri
pneumonia
usual
associ
laboratori
featur
includ
lymphopenia
total
lymphocyt
count
cellsml
lymphopenia
cellsml
patient
arteri
hypoxemia
chest
radiograph
evid
bilater
interstiti
infiltr
highli
characterist
ground
glass
appear
patient
neg
chest
radiograph
make
ill
rel
common
form
pneumonia
associ
falseneg
chest
radiograph
diagnost
yield
induc
sputum
averag
vari
greatli
depend
qualiti
control
yield
bronchoscopi
exce
diseas
uniformli
fatal
treat
tmpsmz
dapsonetrimethoprim
clindamycinprimaquin
appear
equal
effect
treat
patient
moder
sever
diseas
current
recommend
therapi
cap
probabl
effect
pcp
mortal
rate
among
treat
patient
hospit
usual
report
influenza
clearli
common
seriou
viral
airway
infect
adult
term
morbid
mortal
season
epidem
unit
state
commonli
associ
death
ascrib
infect
complic
primarili
bacteri
superinfect
great
pandem
influenza
past
centuri
spanish
flu
respons
million
death
worldwid
asian
influenza
hong
kong
influenza
great
major
death
annual
influenza
epidem
patient
age
year
disproportion
number
resid
chronic
care
facil
common
caus
bacteri
superinfect
pneumonia
era
aureu
princip
caus
hospitalacquir
infect
organ
preval
rapid
identif
test
avail
lead
etiolog
diagnosi
min
sensit
diagnosi
often
made
compar
sensit
basi
typic
symptom
nonvaccin
patient
influenza
epidem
gener
influenza
sever
show
greater
antigen
heterogen
influenza
b
amantadin
rimantadin
appear
reduc
durat
sever
symptom
patient
influenza
drug
activ
influenza
b
zanamivir
oseltamivir
activ
influenza
b
virus
rel
efficaci
neuraminidas
inhibitor
versu
amantadin
rimantadin
treat
prevent
influenza
unknown
clinic
trial
date
show
drug
reduc
durat
fever
day
given
within
h
onset
symptom
antimicrobi
agent
also
effect
influenza
prevent
effect
prophylaxi
annual
administr
vaccin
shown
efficaci
prevent
transmiss
last
influenza
season
efficaci
prevent
reduc
elderli
resid
chronic
care
facil
effect
prevent
mortal
often
report
latter
popul
depend
extent
match
epidem
strain
constitu
vaccin
provoc
report
suggest
vaccin
health
care
provid
chronic
care
facil
import
import
vaccin
patient
anoth
report
show
rate
vaccin
efficaci
reduc
absenc
respiratori
ill
among
hospitalbas
health
care
worker
data
emphas
import
vaccin
strategi
target
popul
greatest
risk
includ
person
age
year
patient
cardiopulmonari
diseas
resid
nurs
home
care
provid
ai
tradit
definit
pleural
empyema
pu
pleural
space
recent
investig
use
pleural
fluid
analys
pleural
effus
ph
usual
indic
need
drainag
complic
occur
case
cap
hospit
patient
cap
incid
empyema
decreas
substanti
preantibiot
era
pneumonia
account
twothird
case
bacteriolog
also
chang
metaanalysi
case
empyema
report
show
pneumonia
isol
case
major
involv
anaerob
bacteria
aureu
andor
gramneg
bacilli
mani
mix
infect
uncertain
mani
cultureneg
case
caus
pneumococci
erad
prior
antibiot
treatment
studi
cap
show
patient
pleural
effus
identifi
routin
chest
radiographi
empyema
infrequ
patient
import
recogn
implic
regard
need
adequ
drainag
critic
compon
effect
manag
author
recommend
thoracentesi
parapneumon
effus
measur
mm
later
decubitu
radiograph
standard
test
perform
pleural
fluid
includ
appropri
stain
cultur
aerob
anaerob
bacteria
well
measur
ph
lactic
dehydrogenas
concentr
leukocyt
differenti
count
particularli
import
ph
determin
fluid
must
obtain
anaerob
place
ice
transport
immedi
laboratori
drainag
requir
pu
pleural
space
posit
gram
stain
cultur
ph
neither
lactic
dehydrogenas
level
glucos
level
sensit
ph
predict
drainag
may
done
chest
tube
imageguid
cathet
thoracoscopi
thoracotomi
rel
merit
indic
use
imageguid
chest
tube
cathet
thrombolyt
thoracoscop
thoracotomi
decort
well
defin
ab
one
common
yet
least
understood
overtr
problem
seen
outpati
set
bronchiti
rank
among
common
condit
seen
outpati
set
account
primari
diagnos
assign
patient
cough
compar
pneumonia
clinic
manifest
ab
may
similar
pneumonia
distinguish
condit
chest
radiographi
paramount
optim
therapi
ab
gener
use
describ
transient
usual
day
durat
respiratori
ill
occur
among
patient
without
chronic
lung
inflammatori
condit
character
cough
without
sputum
fever
andor
substern
discomfort
absenc
radiograph
find
pneumonia
howev
clear
consensu
definit
ab
lack
standard
case
definit
ab
establish
valu
microbiolog
studi
high
rate
spontan
resolut
interfer
establish
firm
diagnosi
ration
implement
appropri
treatment
differenti
diagnosi
cough
requir
consider
infecti
noninfecti
etiolog
among
noninfecti
caus
smoke
asthma
postnas
drip
syndrom
angiotensinconvert
enzym
inhibitor
pollut
cough
due
infect
includ
spectrum
condit
nasopharyng
infect
common
cold
ab
chronic
bronchiti
sinus
pneumonia
better
understand
cough
even
sputum
prolong
expect
part
uncompl
viral
respiratori
infect
necessarili
indic
bacteri
infect
help
practition
patient
avoid
unnecessari
antimicrobi
use
approxim
person
experiment
infect
rhinoviru
experi
cough
promin
symptom
cough
persist
longer
symptom
fact
day
patient
still
cough
auscultatori
find
nonspecif
often
normal
variabl
find
local
rale
wheez
prolong
expiratori
phase
may
note
especi
patient
reactiv
airway
diseas
distinguish
ab
nonseri
pneumonia
import
therapeut
prognost
implic
publish
studi
pneumonia
indic
combin
clinic
find
reliabl
defin
presenc
pneumonia
although
absenc
vital
sign
abnorm
abnorm
chest
auscult
substanti
reduc
likelihood
pneumonia
constel
find
rule
ill
therefor
standard
criterion
differenti
condit
chest
radiographi
syndrom
ab
often
associ
respiratori
virus
antibacteri
therapi
unwarr
howev
wellcontrol
studi
use
modern
diagnost
method
perform
recent
would
enabl
systemat
evalu
role
respiratori
pathogen
common
virus
identifi
common
cold
virus
rhinoviru
coronaviru
other
includ
influenza
viru
adenoviru
parainfluenza
viru
rsv
small
proport
case
nonvir
etiolog
pneumonia
c
pneumonia
bordetella
pertussi
link
ab
littl
evid
pneumonia
h
influenza
import
role
etiolog
ab
adult
communityacquir
infect
absenc
chronic
obstruct
lung
diseas
airway
violat
eg
tracheostomi
immunosuppress
eg
aid
seriou
associ
diseas
cystic
fibrosi
person
acut
exacerb
chronic
obstruct
pulmonari
diseas
semiquantit
analysi
sputum
microscop
examin
cultur
suggest
h
influenza
pneumonia
may
greater
concentr
absenc
exacerb
data
howev
inconsist
exacerb
appear
due
factor
bacteri
infect
valu
antibacteri
agent
treatment
immunocompet
patient
ab
confirm
use
agent
recommend
sever
control
trial
suggest
antibiot
major
patient
cough
due
ab
measur
benefit
conflict
result
clinic
trial
may
explain
variat
methodolog
patient
type
includ
patient
acut
exacerb
chronic
bronchiti
contrast
studi
demonstr
bronchodil
eg
albuterol
effect
antibiot
relief
symptom
despit
inform
antibiot
gener
indic
ab
studi
indic
primari
care
provid
use
major
case
overus
antibiot
increas
pressur
lead
antimicrobi
resist
sever
reason
given
justifi
use
antibiot
ab
patient
expect
possibl
benefit
prevent
secondari
bacteri
infect
possibl
treatabl
caus
ie
infect
mycoplasma
chlamydia
must
rememb
data
show
treatment
organ
favor
effect
bronchiti
addit
recent
studi
found
patient
satisfact
depend
receipt
antibiot
prescript
long
physician
explain
rational
manag
anoth
studi
show
antibiot
abus
case
ab
reduc
physician
patient
warn
consequ
practic
numer
studi
support
recommend
includ
metaanalysi
show
slight
benefit
gain
antibiot
therapi
author
conclud
disadvantag
antibiot
outweigh
modest
benefit
costeffect
accur
rapid
diagnost
test
ie
pcr
throat
swab
specimen
avail
confirm
caus
mycoplasma
chlamydia
idsa
panel
recommend
reserv
antibiot
therapi
ie
macrolid
tetracyclin
patient
sever
persist
diseas
eg
day
durat
reason
likelihood
pertussi
rational
antibiot
treatment
late
cours
pertussi
reduc
transmiss
idsa
panel
agre
other
encourag
physician
identifi
method
decreas
unnecessari
antimicrobi
use
ab
improv
clinic
approach
commun
patient
concern
lack
benefit
possibl
side
effect
develop
resist
associ
therapi
practic
withhold
antibiot
patient
cough
ill
support
literatur
associ
increas
offic
visit
cost
followup
visit
patient
whose
condit
improv
day
balanc
high
likelihood
spontan
resolut
risk
patient
commun
unnecessari
antibiot
use
except
admonit
consider
antiinfluenza
agent
administ
within
h
onset
symptom
increas
appreci
potenti
bioterror
either
dissid
foreign
countri
relev
pneumonia
guidelin
base
observ
sever
microb
could
use
weapon
would
express
pneumonia
number
microb
could
dissemin
biolog
weapon
aerosol
invis
odorless
tasteless
inoculum
could
afflict
mani
thousand
patient
incub
period
day
week
set
etiolog
agent
like
caus
sever
pulmonari
infect
bacillu
anthraci
yersinia
pesti
f
tularensi
tabl
recognit
condit
would
medic
practition
critic
implement
appropri
strategi
establish
diagnosi
treat
afflict
patient
provid
prevent
treatment
expos
thu
first
respond
bioterror
expect
physician
offic
practic
emerg
room
icu
disciplin
infecti
diseas
acknowledg
nation
plan
civilian
medic
public
health
respons
initi
b
anthraci
caus
inhal
anthrax
one
organ
could
use
biolog
terror
caus
concern
environment
stabil
spore
small
inoculum
necessari
produc
fulmin
infect
high
associ
mortal
rate
incub
period
quit
variablemost
case
present
first
sever
day
exposur
incub
period
week
initi
symptom
nonspecif
fever
malais
chest
pain
nonproduct
cough
may
follow
brief
improv
sever
respiratori
distress
shock
death
true
pneumonia
chest
radiograph
often
show
highli
characterist
widen
mediastinum
without
parenchym
infiltr
diagnosi
establish
posit
blood
cultur
may
initi
dismiss
bacillu
contamin
unless
multipl
contamin
singl
facil
sputum
cultur
neg
mortal
rate
without
treatment
fact
mortal
rate
remain
treatment
initi
develop
clinic
symptom
administr
iv
penicillin
high
dose
histor
consid
prefer
therapi
report
engin
resist
publish
thu
empir
treatment
sensit
test
respons
strain
oral
iv
ciprofloxacin
doxycyclin
penicillin
altern
sensit
test
initi
case
may
use
dictat
antibiot
choic
subsequ
patient
treatment
continu
day
potenti
problem
prolong
incub
delay
equal
lethal
diseas
sinc
humantohuman
transmiss
occur
standard
isol
precaut
appropri
particularli
import
prophylaxi
region
exposur
determin
popul
risk
requir
emerg
assess
public
health
offici
prefer
regimen
ciprofloxacin
mg
po
bid
doxycyclin
mg
po
bid
amoxicillin
mg
po
depend
suscept
epidem
strain
prophylaxi
continu
day
ciprofloxacin
doxycyclin
advoc
highli
activ
vitro
establish
efficaci
anim
model
fluoroquinolon
probabl
equal
effect
factor
emphas
possibl
region
suppli
may
limit
largescal
exposur
f
tularensi
caus
infect
per
year
unit
state
caus
hundr
thousand
infect
europ
world
war
ii
potenti
biolog
weapon
substanti
extens
studi
perform
us
biolog
weapon
program
multipl
form
diseas
common
follow
aerosol
exposur
typhoid
pneumon
tularemia
averag
incub
period
day
tabl
symptom
nonspecif
includ
fever
malais
nonproduct
cough
chest
radiograph
show
evid
pneumonia
without
mediastin
adenopathi
tularemia
suspect
organ
may
cultur
blood
sputum
pharyng
exud
difficulti
cultur
media
contain
cystein
sulfhydryl
compound
use
organ
repres
hazard
laboratori
personnel
cultur
attempt
laboratori
usual
method
diagnosi
serolog
posit
second
week
diseas
case
standard
treatment
streptomycin
gentamicin
tetracyclin
chloramphenicol
also
effect
associ
higher
rate
relaps
tetracyclin
use
effect
postexposur
prophylaxi
minim
risk
persontoperson
spread
recommend
prophylaxi
expos
person
administr
tetracyclin
doxycyclin
week
pesti
also
potenti
biolog
weapon
great
concern
fulmin
cours
infect
caus
death
absenc
antibiot
treatment
spread
person
person
clinic
featur
pneumonia
plagu
includ
high
fever
chill
headach
cough
bloodi
sputum
leukocytosi
radiograph
chang
show
bilater
pneumonia
rapid
progress
septic
shock
death
tabl
acut
swollen
tender
lymph
node
bubo
highli
characterist
bubon
plagu
unlik
present
diagnosi
establish
cultur
sputum
blood
sputum
gram
stain
show
typic
safetypin
bipolarstain
gramneg
coccobacilli
health
care
worker
risk
aerosol
exposur
respiratori
precaut
taken
patient
h
therapi
standard
treatment
plagu
pneumonia
administr
streptomycin
gentamicin
standard
dose
day
altern
masscasualti
set
tetracyclin
fluoroquinolon
given
oral
day
administr
tetracyclin
fluoroquinolon
day
prefer
prophylaxi
facetofac
contact
occur
exposur
suspect
licens
plagu
vaccin
found
protect
amelior
pneumon
plagu
role
set
manag
recommend
within
document
restrict
immunocompet
adult
acut
cap
stratifi
basi
whether
patient
treat
outpati
hospit
figur
emphasi
accord
follow
ration
use
microbiolog
laboratori
patient
candid
hospit
acut
pneumonia
blood
cultur
perform
expector
sputum
specimen
collect
presenc
physician
whenev
possibl
antimicrobi
administr
unless
procedur
would
substanti
delay
initi
treatment
bii
consensu
lack
need
microbiolog
diagnosi
outpati
although
prepar
airdri
heatfix
slide
sputum
obtain
antimicrobi
treatment
subsequ
gram
stain
desir
investig
select
microbi
pathogen
legionella
mycobacterium
depend
clinic
featur
pathogendirect
antimicrobi
therapi
attempt
made
achiev
pathogendirect
antimicrobi
therapi
hospit
patient
ciii
tabl
decis
made
relev
inform
becom
avail
strength
greatest
case
establish
etiolog
agent
identifi
accord
criteria
describ
empir
select
antimicrobi
agent
necessari
direct
pathogen
common
treatabl
accord
set
tabl
antibiot
regimen
select
empir
chang
result
cultur
vitro
sensit
test
becom
avail
assumpt
clinic
microbiolog
correl
support
tactic
prompt
antimicrobi
treatment
antimicrobi
treatment
initi
promptli
diagnosi
pneumonia
establish
radiographi
gram
stain
result
avail
facilit
antimicrobi
select
patient
requir
hospit
acut
pneumonia
import
initi
therapi
time
fashion
analysi
patient
show
delay
time
admiss
initi
antibiot
therapi
associ
increas
mortal
bii
antibiot
treatment
withheld
acut
ill
patient
delay
obtain
appropri
specimen
result
gram
stain
cultur
decis
regard
hospit
base
prognost
criteria
summar
tabl
ai
addit
decis
influenc
factor
avail
home
support
probabl
complianc
avail
altern
set
supervis
care
mani
patient
cap
hospit
concurr
diseas
process
studi
show
admiss
cap
consider
extend
beyond
list
admiss
criteria
tabl
diagnost
studi
diagnosi
pneumonia
requir
demonstr
infiltr
chest
radiographi
posteroanterior
later
chest
radiographi
recommend
pneumonia
suspect
aii
although
obtain
radiograph
may
alway
practic
addit
diagnost
studi
patient
candid
hospit
summar
tabl
bii
patient
serious
ill
requir
hospit
desir
perform
sputum
gram
stain
without
cultur
complet
blood
cell
count
differenti
sometim
use
assess
ill
term
detect
sever
infect
presenc
associ
condit
chronic
infect
pathogendirect
therapi
treatment
option
obvious
simplifi
etiolog
agent
establish
strongli
suspect
antibiot
decis
base
microbi
pathogen
summar
tabl
ciii
empir
antibiot
decis
select
antibiot
absenc
etiolog
diagnosi
gram
stain
cultur
diagnost
base
multipl
variabl
includ
sever
ill
patient
age
antimicrobi
intoler
side
effect
clinic
featur
comorbid
concomit
medic
exposur
epidemiolog
set
bii
tabl
prefer
antimicrobi
antimicrobi
agent
prefer
patient
special
order
macrolid
erythromycin
clarithromycin
azithromycin
clarithromycin
azithromycin
prefer
h
influenza
suspect
doxycyclin
fluoroquinolon
levofloxacin
moxifloxacin
gatifloxacin
anoth
fluoroquinolon
enhanc
activ
pneumonia
altern
option
amoxicillinclavulan
secondgener
cephalosporin
cefuroxim
cefpodoxim
cefprozil
appropri
infect
ascrib
pneumonia
h
influenza
agent
activ
atyp
agent
author
prefer
macrolid
doxycyclin
patient
age
year
comorbid
fluoroquinolon
patient
age
year
comorbid
diagnost
studi
diagnost
studi
recommend
hospit
patient
summar
tabl
bii
patient
hospit
acut
pneumonia
blood
cultur
perform
prefer
specimen
obtain
separ
site
min
apart
antibiot
administr
bii
deepcough
expector
sputum
sampl
procur
nurs
physician
obtain
antibiot
administr
bii
sampl
transport
laboratori
gram
stain
cultur
within
h
collect
test
legionella
speci
tuberculosi
pathogen
request
indic
antimicrobi
treatment
initi
promptli
delay
attempt
obtain
pretreat
specimen
microbiolog
studi
acut
ill
patient
biii
induc
sputum
sam
empir
therapi
recommend
empir
treatment
hospit
patient
differ
guidelin
version
regimen
treatment
blactam
plu
macrolid
monotherapi
fluoroquinolon
prefer
rational
recommend
regimen
base
studi
show
regimen
associ
signific
reduct
mortal
compar
associ
administr
cephalosporin
alon
anoth
studi
support
observ
caution
necessari
interpret
studi
sinc
may
reflect
tempor
geograph
differ
studi
suffici
number
patient
treat
macrolid
justifi
conclus
categori
although
recent
studi
suggest
azithromycin
monotherapi
equival
blactam
blactam
plu
erythromycin
recommend
combin
treatment
patient
hospit
icu
base
limit
data
support
monotherapi
macrolid
fluoroquinolon
patient
critic
ill
pneumococc
pneumonia
recommend
treat
cap
suffici
sever
requir
hospit
icu
use
blactam
combin
fluoroquinolon
blactam
combin
macrolid
goal
provid
optim
therapi
commonli
identifi
caus
lethal
pneumonia
pneumonia
legionella
fluoroquinolon
alon
recommend
therapeut
trial
antimicrobi
agent
macrolid
exclud
serious
ill
patient
thu
rigor
collect
clinic
data
concern
serious
ill
patient
limit
prefer
antimicrobi
antimicrobi
agent
prefer
patient
follow
special
order
gener
medic
ward
cefotaxim
ceftriaxon
plu
macrolid
azithromycin
clarithromycin
erythromycin
fluoroquinolon
alon
levofloxacin
gatifloxacin
moxifloxacin
trovafloxacin
anoth
fluoroquinolon
enhanc
activ
pneumonia
fluoroquinolon
vitro
activ
clinic
signific
anaerob
pulmonari
pathogen
includ
trovafloxacin
moxifloxacin
gatifloxacin
icu
blactam
cefotaxim
ceftriaxon
ampicillinsulbactam
piperacillintazobactam
plu
either
macrolid
fluoroquinolon
special
consider
structur
diseas
lung
bronchiectasi
cystic
fibrosi
consid
use
regimen
activ
pseudonoma
aeruginosa
blactam
allergi
consid
regimen
fluoroquinolon
without
clindamycin
suspect
aspir
consid
fluoroquinolon
without
blactam
blactamas
inhibitor
ampicillinsulbactam
piperacillintazobactam
metronidazol
clindamycin
fluoroquinolon
good
vitro
activ
anaerob
may
requir
combin
second
antimicrobi
agent
see
note
fluoroquinolon
previou
paragraph
antibiot
mainstay
treatment
pneumonia
guidelin
select
summar
tabl
bii
bii
base
larg
clinic
experi
andor
vitro
activ
treatment
option
simplifi
etiolog
diagnosi
establish
highli
suspect
basi
result
rapid
test
gram
stain
use
special
stain
antigen
detect
amplif
techniqu
tabl
select
antimicrobi
agent
base
multipl
variabl
includ
sever
ill
patient
age
abil
toler
side
effect
clinic
featur
comorbid
prior
exposur
epidemiolog
set
cost
tabl
well
preval
drug
resist
among
respiratori
tract
pathogen
suggest
regimen
consider
empir
administr
patient
hospit
acut
pneumonia
summar
tabl
distinct
regimen
gener
use
regimen
patient
requir
treatment
icu
bii
follow
discuss
review
salient
issu
blactam
relat
agent
blactam
exert
antibacteri
effect
interf
synthesi
peptidoglycan
compon
bacteri
cell
wall
blactam
inact
pneumonia
c
pneumonia
ineffect
treatment
legionella
antibacteri
spectrum
penicillin
vari
narrowspectrum
agent
activ
larg
limit
gramposit
cocci
penicillin
g
penicillin
v
oxacillin
expandedspectrum
agent
activ
mani
gramneg
bacilli
piperacillin
ticarcillin
mezlocillin
parenter
penicillin
g
parenter
cefotaxim
parenter
ceftriaxon
oral
amoxicillin
gener
view
blactam
drug
choic
treat
infect
pneumonia
penicillin
mic
mg
ml
altern
penicillin
gener
prefer
infect
involv
pneumonia
resist
penicillin
mic
mgml
includ
ampicillin
cefotaxim
ceftriaxon
penicillin
combin
blactamas
inhibitor
amoxicillinclavulan
ticarcillinclavulan
ampicillinsulbactam
piperacillintazobactam
activ
blactamaseproduc
organ
h
influenza
anaerob
catarrhali
combin
offer
advantag
penicillin
g
pneumonia
ticarcillin
less
activ
penicillin
pneumonia
cephalosporin
drug
gener
show
enhanc
activ
aerob
gramneg
bacilli
go
firstto
secondto
thirdgener
agent
antimicrobi
agent
class
activ
strain
pneumonia
cefotaxim
ceftriaxon
clinic
relev
vitro
resist
drug
treat
pneumonia
question
cefuroxim
substanti
less
activ
vitro
cefotaxim
ceftriaxon
anecdot
associ
treatment
failur
parenter
cephalosporin
use
pneumococc
pneumonia
includ
firstgener
agent
cefazolin
cephalexin
thirdgener
drug
ceftizoxim
ceftazidim
oral
cephalosporin
prefer
basi
vitro
activ
pneumonia
cefuroxim
cefpodoxim
cefprozil
secondand
thirdgener
cephalosporin
show
moder
good
activ
h
influenza
catarrhali
cephalosporin
best
vitro
activ
anaerob
gramneg
bacilli
prevotella
bacteroid
speci
cefoxitin
cefotetan
cefmetazol
although
publish
studi
use
drug
anaerob
lung
infect
cephalosporin
less
activ
anaerob
vitro
carbapenem
meropenem
imipenem
activ
broad
spectrum
aerob
anaerob
gramposit
gramneg
organ
includ
strain
pneumonia
p
aeruginosa
virtual
strain
h
influenza
catarrhali
anaerob
methicillinsuscept
aureu
activ
penicillinresist
pneumonia
gener
adequ
macrolid
erythromycin
limit
antimicrobi
spectrum
activ
poorli
toler
gastrointestin
side
effect
newer
macrolid
better
toler
expens
includ
azithromycin
clarithromycin
appear
effect
treat
pulmonari
infect
caus
pneumonia
c
pneumonia
legionella
penicillinresist
pneumonia
isol
resist
macrolid
vitro
rate
substanti
higher
strain
intermediateor
highlevel
penicillin
resist
caution
necessari
empir
use
suspect
case
pneumococc
pneumonia
mechan
macrolid
resist
pneumonia
first
phenotyp
efflux
mechan
associ
mic
mgml
theori
may
overcom
high
dose
mechan
preval
unit
state
second
erm
phenotyp
due
ribosom
alter
associ
mic
mgml
mechan
predomin
europ
case
macrolid
failur
describ
anecdot
infrequ
far
macrolid
reason
good
activ
anaerob
except
fusobacteria
communityacquir
strain
aureu
usual
suscept
macrolid
bacteria
suscept
resist
macrolid
differ
erythromycin
rel
inact
h
influenza
clarithromycin
also
rel
limit
vitro
activ
h
influenza
howev
metabolit
augment
activ
parent
compound
macrolid
azithromycin
activ
agent
vitro
legionella
h
influenza
pneumonia
wherea
clarithromycin
activ
pneumonia
c
pneumonia
azithromycin
erythromycin
avail
iv
administr
multicent
prospect
studi
immunocompet
outpati
cap
show
erythromycin
costeffect
antimicrobi
therapi
recent
trial
show
monotherapi
iv
azithromycin
equival
regimen
cefuroxim
without
erythromycin
patient
hospit
cap
idsa
panel
felt
latter
report
support
azithromycin
initi
empir
treatment
concern
express
particip
ill
compar
arm
ideal
vitro
activ
azithromycin
pneumonia
suboptim
quinolon
current
avail
agent
class
pulmonari
infect
ciprofloxacin
ofloxacin
levofloxacin
sparfloxacin
moxifloxacin
gatifloxacin
trovafloxacin
drug
activ
vitro
clinic
signific
aerob
gramposit
cocci
gramneg
bacilli
h
influenza
catarrhali
legionella
speci
pneumonia
c
pneumonia
levofloxacin
sparfloxacin
moxifloxacin
gatifloxacin
trovafloxacin
show
enhanc
vitro
activ
pneumonia
includ
penicillinresist
strain
initi
clinic
trial
show
good
result
one
studi
show
clinic
outcom
levofloxacin
significantli
better
cephalosporin
regimen
empir
treatment
cap
trovafloxacin
associ
excess
rate
hepatotox
use
gener
restrict
hospit
patient
lack
altern
antibiot
option
sparfloxacin
high
rate
photosensit
reaction
higher
rate
qtinterv
prolong
fluoroquinolon
ciprofloxacin
slightli
less
activ
vitro
anecdot
report
clinic
failur
pneumococc
pneumonia
author
feel
dosag
mg
twice
daili
adequ
empir
use
support
concern
increas
resist
pneumonia
found
report
increas
mic
fluoroquinolon
sequenti
collect
strain
pneumonia
hong
kong
england
ireland
canada
ciprofloxacin
ofloxacin
levofloxacin
gatifloxacin
trovafloxacin
avail
iv
administr
aminoglycosid
aminoglycosid
gentamicin
tobramycin
netilmicin
amikacin
show
concentrationdepend
bactericid
effect
permit
singledailydos
regimen
agent
activ
vitro
aerob
facult
gramneg
bacilli
includ
p
aeruginosa
author
feel
aminoglycosid
use
singl
agent
treat
gramneg
bacillari
pneumonia
poor
clinic
result
may
due
suboptim
dose
possibl
inactiv
drug
acid
environ
site
infect
tetracyclin
multipl
member
class
one
frequent
use
clinic
practic
today
doxycyclin
basi
toler
conveni
twicedaili
dose
good
bioavail
low
price
among
respiratori
tract
pathogen
tetracyclin
activ
vitro
atyp
organ
includ
pneumonia
c
pneumonia
legionella
pneumonia
h
influenza
past
quit
suscept
agent
pneumococci
resist
vancomycin
vancomycin
show
univers
activ
pneumonia
also
activ
gramposit
organ
includ
methicillinresist
aureu
substanti
concern
excess
vancomycin
use
promot
evolut
enterococci
resist
vancomycin
aureu
strain
intermedi
suscept
pneumococc
toler
vancomycin
also
recent
describ
although
clinic
relev
find
unknown
clindamycin
clindamycin
exhibit
good
vitro
activ
gramposit
cocci
includ
pneumococci
resist
macrolid
efflux
pump
mechan
methicillinsuscept
aureu
mani
author
consid
clindamycin
prefer
drug
anaerob
pulmonari
infect
includ
aspir
pneumonia
putrid
lung
abscess
inact
h
influenza
atyp
etiolog
agent
vari
proport
erythromycinresist
aureu
tmpsmz
tmpsmz
activ
vitro
broad
spectrum
gramposit
gramneg
organ
increasingli
lost
efficaci
pneumonia
pneumonia
strain
resist
penicillinresist
pneumonia
isol
suscept
tmpsmz
tmpsmz
activ
divers
pathogen
nocardia
asteroid
p
carinii
stenotrophomona
maltophilia
antivir
agent
amantadin
rimantadin
inhibitor
hemagglutinin
establish
efficaci
treat
prevent
influenza
relenza
oseltamivir
establish
efficaci
treatment
influenza
b
also
appear
effect
prevent
treatment
drug
must
given
within
h
onset
influenza
symptom
therapeut
trial
show
mean
reduct
durat
influenza
symptom
includ
fever
day
substanti
reduct
viral
shed
amantadin
rimantadin
compar
effect
compar
trial
rimantadin
expens
less
cn
toxic
relenza
oseltamavir
recent
fdaapprov
neuraminidas
inhibitor
appear
equal
effect
although
trial
compar
drug
drug
amantadin
rimantadin
report
possibl
advantag
neuraminidas
inhibitor
addit
activ
influenza
b
lack
cn
toxic
reduc
probabl
resist
disadvantag
higher
price
somewhat
awkward
aerosoldeliveri
devic
possibl
wheez
relenza
gastrointestin
side
effect
oseltamivir
idsa
panel
endors
use
antivir
agent
treat
influenza
bi
need
initi
therapi
within
h
requir
rapid
diagnost
test
influenza
detect
empir
treatment
base
typic
clinic
featur
influenza
epidem
drug
influenza
appear
equal
effect
therefor
select
base
avail
toxic
cost
awar
control
trial
specif
address
question
long
pneumonia
treat
decis
usual
base
pathogen
respons
treatment
comorbid
ill
complic
data
forthcom
seem
reason
treat
pneumonia
caus
pneumonia
patient
afebril
h
ciii
pneumonia
caus
bacteria
necros
pulmonari
parenchyma
eg
aureu
p
aeruginosa
klebsiella
anaerob
probabl
treat
week
pneumonia
caus
pneumonia
c
pneumonia
probabl
treat
least
week
legionnair
diseas
immunocompet
individu
bii
azithromycin
may
use
shorter
cours
treatment
long
halflif
tissu
cost
consider
pressur
treat
patient
pneumonia
outsid
hospit
increas
rise
interest
use
oral
therapi
mani
drug
well
absorb
gut
clear
advantag
parenter
therapi
nevertheless
patient
admit
hospit
common
practic
least
begin
therapi
iv
drug
although
studi
verifi
superior
outcom
practic
justifi
concern
absorpt
acut
ill
patient
chang
iv
oral
therapi
associ
number
econom
health
care
social
benefit
reduc
cost
treatment
shorten
length
hospit
stay
numer
random
control
trial
support
practic
provid
patient
condit
improv
clinic
hemodynam
stabl
patient
abl
ingest
drug
gastrointestin
tract
function
normal
ai
case
condit
met
within
day
oral
therapi
given
time
ideal
drug
given
parenter
close
relat
one
given
oral
oral
formul
avail
oral
agent
similar
spectrum
activ
select
basi
vitro
predict
sensit
pattern
establish
probabl
pathogen
gener
matter
idsa
panel
endors
use
bioavail
activ
oral
antimicrobi
agent
patient
whose
medic
condit
stabl
toler
drug
aiii
assess
respons
treatment
expect
respons
treatment
take
account
immunolog
capac
host
sever
ill
pathogen
chest
radiograph
find
subject
respons
usual
note
within
day
initi
treatment
object
paramet
includ
respiratori
symptom
cough
dyspnea
fever
partial
pressur
oxygen
peripher
leukocyt
count
find
serial
radiograph
care
document
respons
fever
time
defervesc
pneumococc
pneumonia
young
adult
averag
durat
fever
treatment
day
bacterem
pneumonia
case
day
elderli
patient
febril
also
appear
longer
patient
pneumonia
usual
afebril
within
day
treatment
wherea
immunocompet
patient
legionnair
diseas
defervesc
averag
day
blood
cultur
case
bacterem
pneumonia
usual
neg
within
h
treatment
pathogen
usual
also
suppress
respiratori
secret
within
h
major
except
p
aeruginosa
gramneg
bacilli
may
persist
despit
appropri
treatment
pneumonia
usual
persist
despit
effect
therapi
followup
cultur
blood
sputum
indic
patient
respond
therapi
except
tuberculosi
chest
radiograph
find
usual
clear
slowli
clinic
find
multipl
radiograph
gener
requir
aii
first
sever
day
treatment
often
radiograph
progress
despit
good
clinic
respons
presum
reflect
continu
inflammatori
chang
even
absenc
viabl
bacteria
followup
radiographi
hospit
may
indic
assess
posit
endotrach
tube
assess
posit
line
exclud
pneumothorax
central
line
placement
determin
reason
failur
respond
pneumothorax
empyema
progress
infiltr
cavit
pulmonari
edema
ard
regard
host
factor
age
presenc
absenc
comorbid
ill
import
determin
rate
resolut
radiograph
patient
bacterem
pneumococc
pneumonia
age
year
clear
week
howev
older
patient
patient
underli
ill
particularli
alcohol
chronic
obstruct
pulmonari
diseas
patient
extens
pneumonia
present
rate
resolut
slow
consider
may
show
clear
week
l
pneumophila
infect
may
take
substanti
longer
clear
infect
show
complet
resolut
week
author
advoc
followup
radiographi
week
treatment
select
patient
age
year
andor
smoker
document
resolut
infiltr
exclud
underli
diseas
neoplasm
patient
fail
respond
patient
fail
respond
condit
deterior
initi
empir
therapi
number
possibl
consid
figur
ciii
incorrect
diagnosi
infect
underli
noninfecti
diseas
infecti
compon
noninfecti
ill
may
account
clinic
radiograph
find
includ
congest
heart
failur
pulmonari
embolu
atelectasi
sarcoidosi
neoplasm
radiat
pneumon
pulmonari
drug
reaction
vascul
ard
pulmonari
hemorrhag
inflammatori
lung
diseas
correct
diagnosi
correct
diagnosi
made
patient
fail
respond
physician
consid
follow
compon
hostdrugpathogen
triad
hostrel
problem
overal
report
mortal
hospit
patient
cap
figur
includ
patient
establish
like
etiolog
diagnosi
treat
appropri
antibiot
mortal
rate
patient
bacterem
pneumococc
pneumonia
caus
penicillinsuscept
strain
pneumonia
treat
penicillin
consist
report
usual
explan
physiolog
event
often
form
cascad
set
motion
revers
simpli
kill
infect
organ
occasion
patient
local
lesion
preclud
optim
respons
obstruct
neoplasm
foreign
bodi
empyema
infrequ
import
caus
failur
respond
complic
includ
advers
drug
reaction
complic
medic
manag
fluid
b
drugrel
problem
whether
specif
pathogen
isol
correct
etiolog
diagnosi
pneumonia
made
patient
appear
respond
physician
alway
consid
possibl
medic
error
inappropri
dose
regimen
problem
complianc
malabsorpt
drugdrug
interact
reduc
antimicrobi
level
factor
may
alter
drug
deliveri
site
infect
drug
fever
anoth
advers
drug
reaction
may
obscur
respons
success
therapi
c
pathogenrel
problem
caus
organ
may
identifi
correctli
may
resist
antibiot
administ
exampl
might
includ
penicillinresist
pneumococcu
methicillinresist
aureu
multiresist
gramnegativebacillu
rod
wide
varieti
pathogen
might
identifi
would
expect
respond
regimen
recommend
empir
use
includ
tuberculosi
fungi
virus
nocardia
c
psittaci
hantaviru
c
burnetii
p
carinii
case
organ
may
repres
copathogen
assess
nonrespond
patient
assess
patient
fail
respond
initi
empir
therapi
take
account
possibl
outlin
figur
test
appropri
individu
diseas
entiti
use
exclud
noninfecti
possibl
specif
exampl
includ
ventilationperfus
lung
scan
select
case
pulmonari
angiographi
identifi
pulmonari
embolu
identif
antineutrophil
cytoplasm
antibodi
bronchoscopi
openlung
biopsi
diagnos
varieti
noninfecti
caus
host
factor
might
influenc
rang
pathogen
well
respons
includ
hiv
infect
cystic
fibrosi
neoplasm
recent
travel
unusu
exposur
case
infect
respons
clinic
radiograph
find
issu
relat
hostdrugpathogen
triad
taken
account
work
rule
endobronchi
lesion
foreign
bodi
bronchoscopi
andor
ct
scan
may
help
ensur
sequest
focu
infect
lung
abscess
empyema
develop
therebi
prevent
access
drug
pathogen
ct
scan
chest
may
use
pleural
effus
detect
chest
radiograph
ultrasonographi
local
collect
provid
estim
volum
fluid
infect
caus
unsuspect
organ
resist
pathogen
must
alway
concern
regard
nonrespond
patient
aggress
attempt
obtain
appropri
expector
sputum
sampl
may
lead
identif
organ
stain
cultur
although
valid
posttreat
specimen
must
question
inabl
cultur
pneumonia
fastidi
pathogen
frequent
overgrowth
aureu
gramneg
bacilli
select
case
bronchoscopi
may
necessari
studi
suggest
help
inform
may
provid
procedur
patient
cap
whose
initi
empir
antimicrobi
therapi
fail
annual
impact
influenza
highli
variabl
winter
influenza
epidem
impact
cap
sizabl
result
primari
influenza
pneumonia
secondari
bacteri
pneumonia
influenza
vaccin
effect
limit
sever
diseas
caus
influenza
viru
recommend
given
annual
person
increas
risk
complic
well
health
care
worker
ai
polyval
vaccin
pneumococc
capsular
polysaccharid
shown
effect
prevent
pneumococc
pneumonia
american
militari
recruit
young
adult
african
male
current
avail
vaccin
effect
prevent
bacterem
pneumococc
infect
immunocompet
adult
efficaci
tend
declin
age
may
unmeasur
immunocompromis
host
despit
controversi
efficaci
fatal
rate
bacterem
pneumococc
infect
among
age
year
andor
varieti
underli
system
ill
remain
high
potenti
benefit
individu
case
deni
vaccin
essenti
free
seriou
side
effect
accordingli
idsa
panel
endors
current
cdc
guidelin
pneumococc
vaccin
bii
half
patient
hospit
pneumococc
diseas
hospit
within
previou
year
unvaccin
patient
risk
factor
pneumococc
diseas
influenza
consequ
vaccin
hospit
whenev
possibl
ciii
contraind
use
either
pneumococc
influenza
vaccin
immedi
episod
pneumonia
ie
hospit
discharg
vaccin
inexpens
given
simultan
follow
recommend
perform
indic
blood
cultur
antibiot
therapi
hospit
patient
studi
indic
complianc
recommend
associ
signific
reduct
mortal
initi
antibiot
therapi
within
h
hospit
prior
studi
indic
complianc
recommend
associ
signific
reduct
mortal
use
cultur
andor
urinari
antigen
test
detect
legionella
speci
patient
hospit
icu
enigmat
cap
demonstr
infiltr
chest
radiographi
imag
techniqu
patient
diagnosi
cap
aid
neutropenia
measur
blood
gase
perform
puls
oximetri
admiss
within
h
admiss
